在高风险的大型B细胞淋巴瘤中适应生物标志物的治疗
Sirpa Leppä1,2, Leo Meriranta1,2, Maare Arffman1,2
1Department of Oncology Helsinki University Hospital Comprehensive Cancer Centre Helsinki Finland.
HemaSphere
|May 13, 2025
概括
高风险的大型B细胞淋巴瘤 (LBCL) 患者在生物标志物导向治疗后的生存率有所改善. 循环瘤DNA (ctDNA) 和TP53状态是治疗反应的关键预后指标.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 高风险的大型B细胞淋巴瘤 (LBCL) 的生存率不够高,特别是在特定的生物风险因素下.
- 目前的治疗策略需要改进,以改善这些患者的治疗结果.
研究的目的:
- 对高风险LBCL患者进行生物标志物驱动的II期试验进行评估.
- 根据生物风险概况,评估R-CHOEP-14和DA-EPOCH-R疗法的疗效.
- 为了研究循环瘤DNA (ctDNA) 动力学和遗传异常的预后价值.
主要方法:
- 一项II期试验招募了123名高风险LBCL患者 (18-64岁).
- 患者根据生物风险因素 (例如,C-MYC转位,TP53删除,MYC/BCL2联合表达) 接受了R-CHOEP-14或DA-EPOCH-R.
- 在治疗期间监测了循环瘤DNA (ctDNA) 水平和动力学.
主要成果:
- 整个队列的三年无故障生存率 (FFS) 和整体生存率 (OS) 分别为79%和88%.
- 在高危患者中,DA-EPOCH-R与R-CHOEP-14相比没有改善生存率.
- 高的治疗前ctDNA,TP53删除/突变,以及治疗结束 (EOT) ctDNA阳性与较差的结果相关.
- EOT ctDNA阴性表明治愈,并解决了错误的阳性PET扫描.
结论:
- 生物标志物导向治疗显示,高风险LBCL患者的生存率有希望.
- TP53异常和高ctDNA水平 (预处理或EOT) 预测预后不佳.
- ctDNA动力学是监测治疗反应和预测结果的宝贵工具.
更多相关视频
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.2K
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
7.8K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411
